Looking for a good penny stock to invest in? Look no further! CTXR stock. Throw all your money at it.
They will be the real winners because they picked a niche. Instead of going for the vaccine they looked to solve a COVID-19 symptom.
Now they are approved by the FDA to be the exclusive license to testing and treatment of stem-cell therapy for any COVID-19 related cases.
“Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that the Company has issued its May 2020 Shareholder Letter. The letter highlights the Company’s exclusive option to license a novel stem-cell therapy to treat acute respiratory distress syndrome (ARDS) associated with COVID-19, and the clinical progress of the Company’s core products: Mino-Lok®, Mino-Wrap™, and Halo-Lido.” – Yahoo! Finance
Currently trading at .87 cents a share, CTXR stock will be up to $1.30 by the end of June. No doubt about it.
Should You Buy CTXR Stock?
About Citius Pharmaceuticals
“Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.” – RobinHood